Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin

Contributed by: Business Wire

Logo

Tags

Research

Genetics

Biotechnology

Other Health

Health

Pharmaceutical

Other Science

Science

Oncology

Ferring Pharmaceuticals

More Like This

For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec

PR Newswire associated0

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

PR Newswire associated0

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets

PR Newswire associated0

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer